Following Sanofi's decision to terminate its proposed acquisition of Maze Therapeutics’ developmental Pompe disease drug, the FTC dismissed its case, ensuring that Maze retains its independence and the market remains competitive for innovative, cost-effective treatments.

On December 12, 2023, Sanofi terminated its licensing deal with Maze Therapeutics after the FTC filed a lawsuit alleging that the collaboration was designed to extend Sanofi’s monopoly in treating Pompe disease. Maze Therapeutics, which had entered the deal to leverage Sanofi’s expertise in accelerating the drug's development for unmet patient needs, now faces setbacks in its innovation efforts.

On December 11, 2023, the FTC initiated an administrative complaint and filed a lawsuit to block Sanofi’s proposed acquisition of an exclusive license for Maze Therapeutics’ Phase 2-ready Pompe disease drug, MZE001. This move is aimed at preserving competition in the rare disease treatment market, ensuring that innovative therapies remain available to patients as an alternative to Sanofi’s monopolistic pricing practices.

Maze Therapeutics' anticipated $750M licensing deal with Sanofi for its investigational Pompe disease therapy collapsed on December 11, 2023, after the FTC sought a preliminary injunction. The company expressed disappointment in response to the regulatory action, a stance that may be seen as a reluctance to embrace regulatory oversight designed to protect competitive and patient-centered market practices.